亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

HBsAg isoforms predict HBsAg seroclearance and finite treatment in patients with chronic hepatitis B after cessation of long-term nucleos(t)ide analogs

医学 乙型肝炎表面抗原 慢性肝炎 免疫学 病毒学 基因亚型 内科学 乙型肝炎 期限(时间) 光学(聚焦) 胃肠病学 乙型肝炎病毒 队列 肝炎 免疫病理学 慢性病 HBeAg
作者
Lung‐Yi Mak,Mark Anderson,Rex Wan‐Hin Hui,Tiffany Fortney,Karen Cheuk-Ying Ho,Rene Geissler,James Fung,Wai‐Kay Seto,Gavin Cloherty,Man‐Fung Yuen
出处
期刊:JHEP reports [Elsevier BV]
卷期号:8 (10): 101989-101989
标识
DOI:10.1016/j.jhepr.2026.101989
摘要

BACKGROUND & AIMS: We examined the role of HBsAg isoforms to predict HBsAg seroclearance or finite treatment among patients with chronic hepatitis B (CHB) infection who stopped long-term nucleoside analog (NUC). METHODS: This prospective study recruited patients with HBeAg-negative non-cirrhotic CHB on ≥3 years of first-line NUC with NUC cessation. NUC was resumed upon clinical relapse (CR) or major virological rebound (mVR). HBV biomarkers were measured at baseline, CR or mVR (if any), and end-of-follow-up. The primary outcome was HBsAg seroclearance (defined as <0.05 IU/ml). Patients were followed up for ≥1 year after NUC cessation (without CR/mVR) or ≥1 year after alanine aminotransferase normalization (with CR/mVR), whichever was later. Finite treatment was defined as a state of no virological relapse (VR), that is persistent HBV DNA <2,000 IU/ml or HBsAg seroclearance. RESULTS: Among 51 patients who completed the study (median age 50.1 years, 62.7% male, baseline qHBsAg 298 IU/ml with 25.5% <100 IU/ml, median NUC duration 7.38 years; median follow-up 91 weeks), six patients developed HBsAg seroclearance at weeks 20, 24, 48, 81, 91, and 96, with an event rate of 11.7%. Baseline small HBsAg (SHBs) was predictive of HBsAg seroclearance (hazard ratio [HR] 0.205, 95% CI 0.082-0.514) and identified 62.5% patients who achieved HBsAg seroclearance when combined with criteria of quantitative HBsAg (qHBsAg) <100 IU/ml. Fifteen patients fulfilled finite treatment criteria, which was associated with low baseline SHBs (HR 3.471, 95% CI 1.132-10.647) and the presence of hepatic steatosis (HR 4.077, 95% CI 1.374-12.098). No patients developed hepatic decompensation. CONCLUSIONS: Baseline small HBs (SHBs) levels, in addition to quantitative HBsAg levels, were predictive of HBsAg seroclearance. SHBs levels and hepatic steatosis were associated with finite treatment following nucleoside analog cessation. IMPACT AND IMPLICATIONS: Stopping long-term nucleoside analog (NUC) is one of the strategies to enhance host control to hepatitis B virus and target for functional cure. In addition to quantitative HBsAg (qHBsAg) levels, we explored the role of HBsAg isoforms in predicting off-therapy outcomes in this prospective cohort study involving Asian patients with chronic hepatitis B infection. Low small HBs, a surrogate marker of integrated DNA-derived HBsAg, was predictive of off-NUC HBsAg seroclearance and identified 62.5% patients who would develop HBsAg seroclearance when combined with qHBsAg <100 IU/ml. Finite treatment, defined as either HBsAg seroclearance or viral load maintained below 2,000 IU/ml after NUC cessation, was associated with low baseline SHBs and presence of hepatic steatosis. Combining qHBsAg <100 IU/ml with low baseline SHBs identified 87.5% patients who could achieve finite treatment. These findings are most compelling to hepatologists and other clinicians managing patients with chronic hepatitis B infection on NUC or researchers conducting clinical trials. The findings are of academic relevance to researchers to investigate the correlation between SHBs expression with intrahepatic viral reservoir as well as the immunological basis behind virological control after NUC cessation. However, the study was limited by a relatively small sample size and the inclusion of purely Asian patients, requiring confirmation in larger cohorts for validation of findings before incorporation into clinical guidelines.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
抚琴祛魅完成签到 ,获得积分10
刚刚
5秒前
何在完成签到,获得积分10
6秒前
Lucas的应助被DTS采纳,获得10
7秒前
9秒前
Ziezer完成签到,获得积分10
10秒前
初初初啊发布了新的文献求助10
10秒前
生性不爱说话完成签到,获得积分10
12秒前
DTS完成签到,获得积分10
14秒前
可爱多婷婷子完成签到 ,获得积分10
14秒前
单身的曲奇完成签到,获得积分10
15秒前
霸气的远望完成签到 ,获得积分10
18秒前
18秒前
Nole的应助被pursuit采纳,获得30
19秒前
迪恩关注了科研通微信公众号
22秒前
初初初啊发布了新的文献求助10
23秒前
reece完成签到 ,获得积分10
25秒前
葡萄味的果茶完成签到 ,获得积分10
27秒前
LeoYiS214完成签到,获得积分10
28秒前
29秒前
31秒前
梨理完成签到 ,获得积分10
32秒前
秀丽战斗机关注了科研通微信公众号
33秒前
33秒前
Nole的应助被科研通管家采纳,获得10
33秒前
33秒前
Hello的应助被科研通管家采纳,获得10
33秒前
33秒前
田様的应助被科研通管家采纳,获得10
33秒前
SciGPT的应助被科研通管家采纳,获得10
33秒前
33秒前
polymer1Ma发布了新的文献求助10
34秒前
隐形曼青的应助被科研通管家采纳,获得10
34秒前
34秒前
尊敬的芷卉完成签到,获得积分10
34秒前
Jasper的应助被科研通管家采纳,获得10
34秒前
34秒前
小蘑菇的应助被科研通管家采纳,获得10
34秒前
PhysicsXX完成签到,获得积分10
36秒前
37秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190060
求助须知:如何正确求助?哪些是违规求助? 9577165
关于积分的说明 21851884
捐赠科研通 7788155
什么是DOI,文献DOI怎么找? 3436233
关于科研通互助平台的介绍 2559935
邀请新用户注册赠送积分活动 2482792